Advanced search
Publication Cover
Immunotherapy Volume 3, 2011 - Issue 4
Submit an article Journal homepage
353
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation

Brentuximab Vedotin for the Treatment of CD30+ Lymphomas

Kelley V Foyil1 Washington University, St Louis School of Medicine, 660 South Euclid Avenue, Campus Box 8056, St Louis, MO63110, USA
&
Nancy L Bartlett1 Washington University, St Louis School of Medicine, 660 South Euclid Avenue, Campus Box 8056, St Louis, MO63110, USACorrespondence[email protected]
Pages 475-485 | Published online: 04 Apr 2011

Bibliography

  • Altekruse SF , KosaryCL, KrapchoM et al.: SEER Cancer Statistics Review, 1975–2007. National Cancer Institute, Bethesda, MD, USA (2010).
  • Martinez C , CanalsC, AlessandrinoE et al.: Relapse of Hodgkin‘s lymphoma (HL) after autologous stem cell transplantation (ASCT): prognostic factors in 462 patients registered in the database of the EBMT.J. Clin. Oncol.28(Suppl. 15) , Abstract 8060 (2010).
  • Vose J , ArmitageJ, Weisenburger D; International T-Cell Lymphoma Project: International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: pathology findings and clinical outcomes. J. Clin. Oncol.26(25) , 4124–4130 (2008).
  • Savage KJ , HarrisNL, VoseJM et al.: ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.Blood111(12) , 5496–5504 (2008).
  • Escalon MP , LiuNS, YangY et al.: Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the MD Anderson Cancer Center experience.Cancer103(10) , 2091–2098 (2005).
  • Gressin R , PeochM, DeconinckE et al.: The VIP-ABVD regimen is not superior to the CHOP 21 for the treatment of non-epidermotropic peripheral T cell lymphoma. Final results of the ‘LTP95‘ protocol of the GOELAMS.Blood108(11) , Abstract 2464 (2006).
  • Schmitz N , TrumperL, ZiepertM et al.: Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.Blood116(18) , 3418–3425 (2010).
  • Kewalramani T , ZelenetzAD, Teruya-FeldsteinJ et al.: Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.Br. J. Haematol.134(2) , 202–207 (2006).
  • Chen AI , McMillanA, NegrinRS, HorningSJ, LaportGG: Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.Biol. Blood Marrow Transplant.14(7) , 741–747 (2008).
  • Le Gouill S , MilpiedN, BuzynA et al.: Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.J. Clin. Oncol.26(14) , 2264–2271 (2008).
  • Corradini P , DoderoA, ZallioF et al.: Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin‘s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.J. Clin. Oncol.22(11) , 2172–2176 (2004).
  • Chiarle R , PoddaA, ProllaG, GongJ, ThorbeckeGJ, InghiramiG: CD30 in normal and neoplastic cells.Clin. Immunol.90(2) , 157–164 (1999).
  • Ansell SM , HorwitzSM, EngertA et al.: Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin‘s lymphoma and anaplastic large-cell lymphoma.J. Clin. Oncol.25(19) , 2764–2769 (2007).
  • Bartlett NL , YounesA, CarabasiMH et al.: A Phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.Blood111(4) , 1848–1854 (2008).
  • Forero-Torres A , LeonardJP, YounesA et al.: A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.Br. J. Haematol.146(2) , 171–179 (2009).
  • Blum KA , JohnsonJL, Jung S-H, Cheson BD, Bartlett NL: Serious pulmonary toxicity with SGN-30 and gemcitabine, vinorelbine, and liposomal doxorubicin in patients with relapsed/refractory Hodgkin lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502. Blood112(11) , Abstract 232 (2008).
  • Younes A , RomagueraJ, HagemeisterF et al.: A pilot study of rituximab in patients with recurrent, classic Hodgkin disease.Cancer98(2) , 310–314 (2003).
  • Copeland AR , CaoY, FanaleM et al.: Final report of a Phase-II study of rituximab plus ABVD for patients with newly diagnosed advanced stage classical Hodgkin lymphoma: results of long follow up and comparison to institutional historical data.Blood114(22) , Abstract 1680 (2009).
  • Thertulien R , FrankelA, EvensA et al.: A Phase I, open-label, dose-escalation, multidose study of MDX-1401 (defucosylated human antiCD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed Hodgkins lymphoma. AACR Meeting Abstracts Abstract 1227 (2009).
  • Blum KA , SmithM, FungH et al.: Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: safety, pharmacokinetics (PK), immunogenicity, and efficacy.J. Clin. Oncol.27(Suppl. 15) , Abstract 8531 (2009).
  • Younes A : Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.Hematol. Am. Soc. Hematol. Educ. Program
  • Younes A , BociekRG, KuruvillaJ et al.: Mocetinostat (MGCD0103), an isotype-selective histone deacetylase (HDAC) inhibitor, produces clinical responses in relapsed/refractory Hodgkin lymphoma (HL): update from a Phase II clinical study.Blood116(21) , Abstract 1763 (2010).
  • Dickinson M , RitchieD, DeAngeloDJ et al.: Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma.Br. J. Haematol.147(1) , 97–101 (2009).
  • Copeland A , BuglioD, YounesA: Histone deacetylase inhibitors in lymphoma.Curr. Opin. Oncol.22(5) , 431–436 (2010).
  • Sureda A , YounesA, Ben-YehudaD et al.: Final analysis: Phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoetic stem cell transplant.Blood116(21) , Abstract 419 (2010).
  • Younes A , HernandezF, BociekRG et al.: ENGAGE- 501: Phase 2 study investigating the role of epigenetic therapy with entinostat (SNDX-275) in relapsed and refractory Hodgkin‘s lymphoma (HL), interim results.Blood116(21) , Abstract 3959 (2010).
  • Younes A , CopelandAR, FanaleMA et al.: Phase I/II study of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and non-Hodgkin lymphoma.Blood116(21) , Abstract 3964 (2010).
  • Motzer RJ , EscudierB, OudardS et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial.Lancet372(9637) , 449–456 (2008).
  • Dutton A , ReynoldsGM, DawsonCW, YoungLS, MurrayPG: Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin‘s lymphoma cells through a mechanism involving Akt kinase and mTOR.J. Pathol.205(4) , 498–506 (2005).
  • Jundt F , RaetzelN, MullerC et al.: A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein β and NF-κB activity in Hodgkin and anaplastic large cell lymphomas. Blood106(5) , 1801–1807 (2005).
  • Yee KWL , ZengZ, KonoplevaM et al.: Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.Clin. Cancer Res.12(17) , 5165–5173 (2006).
  • Johnston PB , InwardsDJ, ColganJP et al.: A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.Am. J. Hematol.85(5) , 320–324 (2010).
  • Bartlett JB , DredgeK, DalgleishAG: The evolution of thalidomide and its IMiD derivatives as anticancer agents.Nat. Rev. Cancer4(4) , 314–322 (2004).
  • Fehniger TA , LarsonS, TrinkausK et al.: A Phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.Blood114(22) , Abstract 3693 (2009).
  • Kuruvilla J , TaylorD, WangL, BlattlerC, KeatingA, CrumpM: Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma.Blood112(11) , Abstract 3052 (2008).
  • Boll B , FuchsM, ReinersKS, EngertA, BorchmannP: Lenalidomide in patients with relapsed or refractory Hodgkin lymphoma.Blood116(21) , Abstract 2828 (2010).
  • Boll B , BorchmannP, ToppMS et al.: Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma.Br. J. Haematol.148(3) , 480–482 (2009).
  • Tempescul A , Ianotto J-C, Guillerm G, Berthou C: ESAP-lenalidomide – a highly active regimen in refractory or relapsed Hodgkin‘s lymphoma. Blood114(22) , Abstract 4797 (2009).
  • Enblad G , HagbergH, ErlansonM et al.: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.Blood103(8) , 2920–2924 (2004).
  • Gallamini A , ZajaF, PattiC et al.: Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.Blood110(7) , 2316–2323 (2007).
  • Dang NH , ProB, HagemeisterFB et al.: Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.Br. J. Haematol.136(3) , 439–447 (2007).
  • Foss FM , Sjak-ShieNN, GoyA, AdvaniR, JacobsenED: Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial.J. Clin. Oncol.28(Suppl. 15) , Abstract 8045 (2010).
  • O‘Connor OA , HorwitzS, HamlinP et al.: Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.J. Clin. Oncol.27(26) , 4357–4364 (2009).
  • O‘Connor O , ProB, Pinter-BrownL et al.: PROPEL: Results of the pivotal, multicenter, Phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).J. Clin. Oncol.27(Suppl. 15) , Abstract 8561 (2009).
  • Horwitz SM , VoseJM, AdvaniR et al.: Pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies: Phase 1 results.Blood114(22) , Abstract 1674 (2009).
  • Coiffier B , HorwitzS, WhittakerS et al.: Romidepsin experience in 317 patients with T-cell lymphomas. In:Proc. Eur. Hematol. Assoc. Abstract 0572 (2010).
  • Coiffier B , ProB, PrinceHM et al.: Final results from a pivotal, multicenter, international, open-label, Phase 2 study of romidepsin in progressive or relapsed peripheral T-Cell lymphoma (PTCL) following prior systemic therapy.Blood116(21) , Abstract 114 (2010).
  • Zhang QL , WangL, ZhangYW et al.: The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.Leukemia23(8) , 1507–1514 (2009).
  • Heider U , RademacherJ, LamottkeB et al.: Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.Eur. J. Haematol.82(6) , 440–449 (2009).
  • Dueck G , ChuaN, PrasadA et al.: Interim report of a Phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.Cancer116(19) , 4541–4548 (2010).
  • Johnston PB , AnsellSM, ColganJP et al.: mTOR inhibition for relapsed or refractory Hodgkin lymphoma: promising single agent activity with everolimus (RAD001).Blood110(11), Abstract 2555 (2007).
  • Wahl AF , KlussmanK, ThompsonJD et al.: The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin‘s disease.Cancer Res.62(13) , 3736–3742 (2002).
  • Tian ZG , LongoDL, FunakoshiS et al.: In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts.Cancer Res.55(22) , 5335–5341 (1995).
  • Cerveny CG , LawCL, McCormickRS et al.: Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin‘s disease cells to conventional chemotherapeutics.Leukemia19(9) , 1648–1655 (2005).
  • Oflazoglu E , KisslerKM, SieversEL, GrewalIS, GerberHP: Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma.Br. J. Haematol.142(1) , 69–73 (2008).
  • Pettit GR : The dolastatins.Fortschr. Chem. Org. Naturst70 , 1–79 (1997).
  • Otani M , NatsumeT, WatanabeJI et al.: TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death.Jpn J. Cancer Res.91(8) , 837–844 (2000).
  • Doronina SO , TokiBE, TorgovMY et al.: Development of potent monoclonal antibody auristatin conjugates for cancer therapy.Nat. Biotech.21(7) , 778–784 (2003).
  • Francisco JA , CervenyCG, MeyerDL et al.: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.Blood102(4) , 1458–1465 (2003).
  • Okeley NM , MiyamotoJB, ZhangX et al.: Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.Clin. Cancer Res.16(3) , 888–897 (2010).
  • Younes A , BartlettNL, LeonardJP et al.: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.N. Engl. J. Med.363(19) , 1812–1821 (2010).
  • Cheson BD , PfistnerB, JuweidME et al.: Revised response criteria for malignant lymphoma.J. Clin. Oncol.25(5) , 579–586 (2007).
  • Fanale M , BartlettNL, Forero-TorresA et al.: The antibody-drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a Phase 1 weekly dosing study.Blood114(22) , Abstract 2731 (2009).
  • Chen R , GopalAK, SmithSE et al.: Results of a pivotal Phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma.Blood116(21) , Abstract 283 (2010).
  • Shustov AR , AdvaniR, BriceP et al.: Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma.Blood116(21) , Abstract 961 (2010).
  • Bartlett N , GroveLE, KennedyDA, SieversEL, Forero-TorresA: Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: a case series.J. Clin. Oncol.28(Suppl. 15) , Abstract 8062 (2010).
  • Bartlett NL , GroveLE, KennedyDA, SieversEL, Forero-TorresA: Objective responses with SGN-35 (brentuximab vedotin) retreatment in CD30-positive hematologic malignancies: a case series. Presented at: 8th International Symposium on Hodgkin Lymphoma, Haematologica. Cologne, Germany, 23–26 October 2010.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.